Ligand Pharmaceuticals (LGND) Current Leases (2010 - 2026)

Ligand Pharmaceuticals (LGND) has 15 years of Current Leases data on file, last reported at $1.1 million in Q1 2026.

• For the quarter ending Q1 2026, Current Leases rose 26.66% year-over-year to $1.1 million; the trailing twelve-month figure through Mar 2026 stood at $1.1 million (up 26.66% YoY), and the FY2025 full-year result was $1.1 million, down 13.51% from the prior year.
• Current Leases declined to $1.1 million in Q1 2026, from $1.1 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $2.3 million in Q3 2022 to a low of $24000.0 in Q2 2025.
• A 5-year average of $787235.3 and a median of $859000.0 in 2025 frame the typical range for Current Leases.
• Peak annual rise in Current Leases reached 5111.11% in 2022, while the deepest fall reached 99.04% in 2022.
• Tracing LGND's Current Leases over 5 years: stood at $670000.0 in 2022, then sank by 39.85% to $403000.0 in 2023, then surged by 214.14% to $1.3 million in 2024, then declined by 13.51% to $1.1 million in 2025, then slipped by 0.64% to $1.1 million in 2026.
• Business Quant data shows LGND's Current Leases at $1.1 million in Q1 2026, $1.1 million in Q4 2025, and $1.1 million in Q3 2025.